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Increased low density lipoprotein oxidation in stable kidney transplant
recipients. We studied factors that may add to the high risk of atheroscle-
rosis in kidney transplant recipients. Plasma lipoprotein concentrations
and parameters of low density lipoprotein (LDL) oxidation were deter-
mined in 19 clinically stable kidney recipients and 19 healthy controls.
Plasma triglycerides and total cholesterol were increased in the patients.
High density lipoprotein-cholesterol (HDL-c) was in the normal range.
The mean LDL diameter was smaller in patients than in controls (236.5
7.3 A vs. 247.8 11.6 A, P < 0.002), which was due to a higher frequency
of the LDL subclass pattern B in the patients than in controls (58% vs.
28%). The lag time of copper-induced in vitro LDL oxidation was shorter
in patients than in controls (101 23mm vs. 148 81 mm, = 0.02). The
titer and concentration of autoantihodies against malondialdehyde-mod-
ified (MDA-LDL) determined by ELISA were higher in the patients than
in the controls. This difference was found in both IgG (titer + 9%,
concentration + 75%; P < 0.05) and 1gM (titer + 35%, concentration +
102%;P < 0.001). Based on these results, we propose that there is in vitro
and in viva evidence of enhanced LDL oxidation in patients post-renal
transplantation. This might represent one cause for the clinical finding of
advanced atherosclerosis in these patients.
Cardiovascular atherosclerosis is frequently found in patients
with chronic renal insufficiency. If atherosclerosis is present
before transplantation, it continues to progress after renal trans-
plantation [1]. Several factors may contribute to the progression
of the atherosclerosis [21. Before transplantation, most patients
are suffering from chronic renal failure, which is associated with a
high incidence of atherosclerosis [3, 4]. After transplantation,
there is an increased prevalence of the well-established risk
factors, hypertension [5, 61 and hyperlipidemia [7—9]. Besides
increased plasma lipoprotein concentrations, alterations in the
composition [10] and susceptibility for oxidation [11] of the
lipoproteins may also play a role in the atherosclerosis in kidney
transplantation patients. Chemical modification of LDL, includ-
ing oxidation, probably precedes the uptake of LDL by macro-
phages and the accumulation of cholesterol in the arterial wall
[12, 13]. The presence of oxidatively modified LDL in atheroscle-
rotic lesions supports this hypothesis [14—16]. The susceptibility of
LDL for oxidation can be determined in vitro [17]. As a measure
of the susceptibility of LDL for oxidation, the time that elapses
before lipid peroxidation products become detectable (lag phase)
can be measured [171. The susceptibility of LDL for oxidation may
be one factor determining LDL oxidation in vivo. The lag phase
was found to be correlated with the extent of coronary athero-
sclerosis in humans [18]. Human plasma contains autoantibodies
against epitopes of oxidized LDL [19, 20]. The level of these
antibodies may also reflect the rate of LDL oxidation [19].
Progression of peripheral atherosclerosis correlates with the titer
of these antibodies [20].
The lipoproteins in the LDL density range form a heteroge-
neous population of different sized particles [21—24]. LDL may be
separated by size via gradient gel acrylamide electrophoresis;
several LDL subclasses are distinguished in this manner [22]. If
the LDL fraction contains mainly large LDL, this is designated as
the LDL subclass pattern A. The presence of mainly small-dense
LDL is indicated as the LDL subclass pattern B [25, 26]. The
pattern B is associated with a high plasma triglycerides and a low
HDL cholesterol concentration, and is partly determined by
genetic factors [25, 26]. Subjects with the LDL subclass pattern B
have an increased risk of coronary heart disease [25—29]. The
atherogenicity of small-dense LDL may be due to its association
with increased plasma triglycerides and lowered HDL cholesterol.
On the other hand, small LDL may play a role in the onset or
progression of CHD due to the physical and physiological prop-
erties of this LDL. Small LDL has a different carbohydrate
composition than large LDL [30]. This may lead to an enhanced
uptake of small LDL by intima-media [31]. In addition, small LDL
is more prone to oxidative modification than larger LDL [32, 331.
Therefore, the LDL subclass pattern, the susceptibility of LDL for
oxidation in vitro, and the level of autoantibodies to epitopes of
oxidized LDL seem to be indicators of in vivo LDL oxidation.
Besides the LDL cholesterol concentration, these variables may
reflect the atherogenicity of the LDL fraction.
In this study, we determined these variables in renal transplan-
tation recipients and matched controls.
Methods
Study population
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We studied 19 stable kidney transplant recipients (13 males, 6
females) and 19 controls, matched for sex, age, and body mass
index. The patients were considered to be in a stable condition if
no rejection episodes or increase in serum creatinine of more than
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Table 1. Characteristics of patient and control groups
Patients Controls
Males N 13 13
Females N 6 6
Age years
Body mass index kg/rn2
42.2 12.3
24.9 3.5
47.3 9.1
25.6 3.1
Time after transplantation m 24 5 —
Cyclosporin dose mg/kg/day 5.5 1.7 —
Prednisone dose mg/day 9.6 2.1 —
Serum creatinine ji.si 155 44 76 9
Creatinine clearance mI/mm 59 22 116 29
Systolic blood pressure mm Hg 149 20 —
Diastolic blood pressure mm Hg 97 14 —
20 j.tmol/Iiter had occurred in the six months before blood
sampling. None of the patients were treated with high doses of
corticosteroids during this period. Exclusion criteria were the
presence of proteinuria or diabetes. Before transplantation, one
patient had been suffering of angina pectoris and one patient of
intracerebral hematoma. The other patients had no cardiovascu-
lar problems before transplantation. At the time of blood sam-
pling none of the patients showed signs of cardiovascular disease
except hypertension. Nine patients were treated with calcium
antagonists, nine with labetalol and one with metoprolol. All
antihypertensive drugs were discontinued for at least three days
before blood sampling.
None of the control subjects had overt atherosclerosis or used
antihypertensive drugs. Table 1 shows demographic data of
patients and controls.
Blood sampling
Blood samples were drawn into EDTA containing polypro-
pylene tubes (final concentration EDTA, 1 mg/mI) on ice. Plasma
was obtained by low speed centrifugation at 4°C. To the plasma
sucrose (10 1.d sucrose solution/mi plasma) was added to a final
concentration of 0.6% to prevent LDL aggregation [34]. Plasma
was stored at —80°C until use.
Separation of plasma lipoproteins
Low density lipoproteins for oxidation experiments were iso-
lated by density gradient ultracentrifugation as described by
Redgrave, Roberts and West [35]. To prevent oxidation of the
lipoproteins during ultracentrifugation 0.1 mivi EDTA and 0.005%
thiomersal were added to the gradient solutions. Before use, the
solutions were gassed by nitrogen to remove the oxygen. All runs
were for 24 hours at 15°C and 40,000 rpm in SW 41 TI Beckman
rotor using polyallomere tubes. HDL cholesterol was determined
after precipitation of apoB containing lipoproteins with heparin/
MnC12 [36]. The plasma LDL cholesterol concentration was
calculated using the Friedewald formula [37].
Low density lipoprotein oxidation
Immediately after isolation part (300 i.tl) of the LDL fraction
was placed in a microdialysis apparatus. Six samples were simul-
taneously dialyzed against 120 ml phosphate buffered saline (PBS,
0.15 M NaC1, 0.01 M phosphate, pH 7.4) for 48 hours at 4°C in the
dark. The dialysis buffer was refreshed after 24 hours. The LDL
cholesterol content was measured and the samples were diluted
with PBS to a final concentration of 0.25 jtM LDL-cholesterol.
The LDL oxidation experiments were carried out as described by
Esterbauer et al [17]. Six samples of LDL were measured simul-
taneously in a thermostated Perkin-Elmer Lambda 5 spectropho-
tometer at 25°C. Oxidation was initiated by the addition of a
freshly prepared copper chloride solution (final concentration
1.66 M). LDL oxidation was followed by monitoring the change
in absorbance at 234 nm every two minutes for 16 hours. The lag
time was defined as the interval between initiation of the reaction
and the intercept of the tangent of the slope of the absorbance
curve with the time scale axis expressed in minutes.
LDL size and subclass determination
The LDL subclass patterns were identified by electrophoresis
on 2 to 16% PAGE gels, as described by Austin et al [251. The gels
were prepared with an LKB 11300 Ultrograd gradient mixer [381.
In each gel, reference sera with known subclass pattern were
applied to lane one and six of a total 12 lanes. The gels were
stained with Oil Red 0 for lipid and the subclass pattern
determination.
For the determination of the LDL size, a set of standard
proteins with known hydrated diameters was run on the same gel
as the samples. The standard proteins (HMW electrophoresis
calibration kit; Pharmacia, Piscataway, NJ, USA) were thyroglob-
ulin (170 A), ferritin (122 A) and catalase (104 A). The gels were
stained with Coomassie Brilliant Blue R 250. The center of the
most prominent LDL band was marked on the gel. The migration
distance of the bands from the top of the gel was measured. The
average LDL particle diameter was estimated from a quadratic
extrapolation of a plot of the logarithm of the diameter of the
standards versus the migration distance of the standards [39].
Autoantibodies against malondialdehyde-modified LDL
Malondialdehyde-modified LDL (MDA-LDL) was prepared as
described by Palinski et a! [40].
Concentrations of autoantibodies against MDA-modified LDL
were determined by ELISA [41]. The method was modified after
the solid-phase radioimmunoassay as described by Salonen et al
[20]. Microtiter plates with high binding capacity (Greiner no.
655061) were coated with 50 jxl MDA-LDL (LDL-cholesterol =
14 to 16 .rM) or native LDL at the same concentration in
phosphate buffered saline (PBS: 0.15 M NaC1, 0.05 M phosphate,
pH 7.4) containing 0.27 mrvi EDTA and 20 tLM butylated hydroxy-
toluene (BHT) for two hours at 37°C. After incubation, each plate
was washed with PBS containing 0.05% Tween-20 and 0.001%
aprotinin using a microplate washer (Biorad model 1550). The
remaining binding sites were blocked with 150 1.d 2% bovine
serum albumin (BSA) in PBS for two hours at room temperature.
The BSA-solution was heated at 56°C for 30 minutes, filtered over
a paper filter and cooled to room temperature before use. Each
plate was washed as described above. Duplicate plasma samples in
dilution of 1/1667 for 1gM class and 1/833.3 for IgG class, in a total
volume of 50 isl were added to the wells and incubated overnight
at 4°C. Wells not incubated with MDA-LDL were used as a blank.
The next day the wells were aspirated and washed again as
described above. Fifty microliters of a thousand-fold diluted
monoclonal mouse antibody against human 1gM or IgG (Sigma
Immunochemicals, St. Louis, MO, USA) in PBS was added and
the plates were incubated for four hours at 4°C and subsequently
washed as described above. Fifty microliters of a peroxidase
conjugated goat anti-mouse antibody (Tago Inc., Burlingname,
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Table 2. Lipids and lipoproteins in renal transplant recipients
and controls
Kidney
Variable recipients Controls P value
Total cholesterol 5.91 0.95 5.33 0.50 0.017
Total triglyceride 2.40 0.99 1.43 0.65 0.001
HDL-cholesterol 1.09 0.39 1.21 0.23 0.28
LDL-cholesterol 3.73 0.70 3.44 0.44 0.13
All variables are in mri standard deviation.
CA, USA) were added to the wells in a thousand-fold dilution in
PBS and incubated for one hour at 37°C, followed by the washing
procedure. For the substrate reaction, an orthophenylenediamine
dihydrochioride solution (2 mg/mI) (Sigma Chemical Co., St.
Louis, MO, USA) in citric acid (0.1 at) phosphate (0.2 M) buffer
(pH 5.5), containing 0.015% hydrogen peroxide was prepared just
before use. Fifty microliters of the substrate solution were added
to each well and incubated in the dark during exactly 20 minutes.
The reaction was stopped with 50 jxl 2.5 M H2S04 per well.
Absorbance was measured using a microplate reader (Biorad
model 450) at 490 nm. The absorbance was linear with the amount
of diluted plasma added up to 100 1.d. The antibody titer was
defined as the absorbance of the wells coated with MDA-LDL
divided by the absorbance of the wells coated with native LDL for
each plasma sample [20]. The concentration of MDA specific
autoantibodies was calculated from the difference in absorbance
between the MDA-LDL coated wells and native LDL coated wells
for each sample. The absorbances were converted in tg anti-
body/ml plasma by comparison with a standard curve of a pooi
plasma with known anti-MDA-LDL antibody concentrations
(1gM 27.0 2.0 jxg/ml, IgG 5.8 0.1 jxg/ml) [41].
Other analytical methods
Plasma cholesterol and triglycerides (Boehringer Mannheim,
Mannheim, Germany) and creatinine (Sigma Diagnostics, St.
Louis, MO, USA) were determined using commercially available
test kits. An estimate of the creatinine clearance rate was calcu-
lated from the plasma creatinine concentration as described by
Cockcroft and Gault [42].
Statistical analysis
Data are presented as means SD. Differences between groups
were evaluated for significance using the Student-t-test or by
ANOVA followed by Bonferoni for comparison of groups. Simple
correlations between variables were calculated using the Pearson
correlation test. The level of significance was set at P < 0.05.
Results
Lipids and lipoproteins in renal transplant recipients and controls
Plasma triglyceride and cholesterol levels were significantly
higher in renal transplant recipients than in controls (68% and
12%, respectively; Table 2). In 47% (9 of 19) of the patients,
cholesterol was > 6.2 mat (240 mg/dl), while in the control group
only one subject had a cholesterol of 6.2 mat. LDL cholesterol
tended to be higher in the patients than in the controls (+ 8%,
P = 0.13). In 37% (7 of 19) of the patients and in one control LDL
cholesterol was > 4.0 mat (155 mg/dl). The mean HDL cholesterol
in the patients was not different from controls.
Table 3. Low density lipoprotein size and subclass patterns in kidney
transplant patients and controls
Variable
Patients
(19)
Controls
(19)
LDL size (A) 236.5 7.3° 247.8 11.6
LDL subclass
Pattern A 6b 13
Pattern A/B 2 1
Pattern B ii
Significantly different from controls (° Student's t-test, P < 0.002,
h Chi-square test, P = 0.028)
Table 4. Lipids and lipoproteins in subjects with different LDL
subclass patterns
Variable Pattern A Pattern A/B Pattern B
Total triglyceride 1.39 0.58 1.75 0.21 2.60 1.00°
Total cholesterol 5.40 0.74 5.40 0.40 5.91 0.87
LDL-cholesterol 3.52 0.53 3.51 0.61 3.68 0.69
HDL-cholesterol 1.24 0.26 1.07 0.08 1.06 0.39
All variables are in m.
Statistically significant difference between LDL subclass pattern A and
B, P < 0.001
LDL size and subclass pattern
The mean size of the most prominent LDL fraction was
significantly less in the patients than in controls (Table 3). The size
of LDL was inversely correlated with the plasma triglyceride (r =
—0.66, P < 0.001) and weakly positively with HDL cholesterol
(r = 0.34, P < 0.05). The smaller size of the LDL particles was
reflected in the LDL subclass pattern. The LDL subclass pattern
B, with a mean diameter of the major LDL subfraction of 233.3
3.1 A, was more frequently found in the patients (58%) than in the
controls (29%)(Pearsons chi-square test, P 0.028, Table 3). The
LDL subclass pattern A (mean particle diameter 250.9 9.2 A)
was present in 26% of the patients and in 68% of the controls. The
mean size of the major LDL fraction in the LDL subclass pattern
A and B in controls and patients were not significantly different
(controls vs. patients, pattern A 253.4 9.2 A vs. 245.6 6.1 A,
pattern B 235.9 3.6 A vs. 232.1 2.2 A). An intermediate LDL
subclass pattern was found in two patients and in one control.
The LDL subclass pattern B was associated with a higher
plasma triglyceride and a lower HDL cholesterol (Table 4).
Considering a plasma triglyceride above 2.3 m and HDL cho-
lesterol beneath 0.9 mat as abnormal, in 7 patients small-dense
LDL together with decreased HDL cholesterol and increased
plasma triglyceride was found, in contrast to the control group in
which only one subject met these criteria. LDL cholesterol was
similar among subjects with different LDL subclasses. There was
no relation between LDL size and LDL cholesterol or total
plasma cholesterol (not shown).
Low density lipoprotein oxidation
The susceptibility of LDL to oxidation was determined by
following in vitro Cu2-induced LDL oxidation. In the kidney
recipients the lag time was 32% shorter than in controls (Table 5).
In subjects with an LDL subclass pattern B the lag phase was
significantly shorter than in subjects with an LDL subclass pattern
A (—38%; Table 5). In patients and controls with the same
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Table 5. Lag time of low density lipoprotein oxidation in vitro
Kidney
LDL subclass All recipients Controls
All 124 63 (38) 101 23 (19) 148 81 (19)
Pattern A 154 78 (19) 122 30(6) 169 80(13)
Pattern A/B 94 10 (3) 94 15 (2) 97 (1)
Pattern B 95 15 (16)' 92 11(11) 102 21(5)
Given are the lag times in mm. Between brackets the number of samples
is shown.
Significantly different from b (ANOVA followed by Bonferoni, P <
0.02
Statistically significant difference between patients and controls, P =
0.02
subclass pattern, the lag time tended to be shorter in the patients
but the differences were not statistically significant (Table 5).
There was no correlation between plasma LDL cholesterol and
lag time in neither controls nor patients (not shown).
Autoantibodies against MDA-modified LDL
Concentrations and titers of autoantibodies against MDA-LDL
were significantly higher in renal transplant patients than in
controls (Table 6). 1gM autoantibody concentrations in the pa-
tients were on the average about twofold higher than in the
controls. IgG autoantibodies were 75% higher in the renal
transplant group. The titer of the 1gM autoantibodies against
MDA-LDL was 35% and of the IgG autoantibodies 9% higher in
the patients than in the controls, both being statistically signifi-
cantly different (Table 6). In patients with an LDL subclass
pattern B 1gM antibody values were higher than in subjects with
the pattern A, 1gM antibodies pattern B versus pattern A 48.3
17.6 xg/ml versus 26.2 10.0 .tg/m1 (P < 0.001), 1gM antibody
titers 2.11 0.35 versus 1.58 0.21 (P < 0.001). Pattern A and
pattern B subjects did not differ in IgG autoantibodies. There was
no correlation between LDL cholesterol and any of the antibody
parameters nor between the plasma cyclosporine A content and
any of the determined variables (not shown).
Discussion
In kidney transplant recipients varying degrees of hyperlipid-
emia have been reported [2, 43—48], with HDL cholesterol being
lowered, enhanced or unaffected [10, 47, 48]. Our study group,
which consisted of patients in a stable condition, resembled the
average lipid profile in kidney transplant patients with an in-
creased plasma cholesterol [>6.2 mtvi (240 mg/dl)] in 47% of the
patients. Since plasma triglyceride was elevated part of the
hypercholesterolemia was attributable to an increase in VLDL
cholesterol. Still, 37% of the patients had an LDL cholesterol
above 4 mrvt (155 mg/dl). Kidney transplantation is associated with
an increased occurrence of atherosclerosis. Several factors are
associated with the atherosclerosis, hypercholesterolemia being
one of them [2]. Over the years it has become clear that in
addition to an enhanced LDL cholesterol other lipoprotein-
associated factors are related with the risk of atherosclerosis.
Oxidation of LDL is considered to be the major event in the
development of atherosclerosis. We found that parameters of in
vitro (lag phase of LDL oxidation) and in vivo (autoantibodies
against MDA-LDL) LDL oxidation are greatly affected in renal
transplant patients, indicating that LDL oxidation may be in-
Table 6. Autoantibodies against MDA-LDL in renal transplant patients
and controls
Variable Kidney recipients Controls P value
Antibody concentration
1gM pg/mi 49.4 15.9 24.4 8.7 <0.0001
IgG pg/mi 5.6 3.8 3.2 1.9 <0.02
Antibody titer
1gM 2.10 0.32 1.56 0.22 <0.0001
IgG 1.25 0.19 1.15 0.10 <0.05
creased in these patients. We, therefore, think that one cause of
the aggravated atherosclerosis in renal transplant patients may be
an increased LDL oxidation. Recently, Maggi and coworkers
reported enhanced levels of autoantibodies against MDA-LDL in
patients during chronic hemodialysis [49]. During this treatment,
which often precedes transplantation, atherosclerosis is probably
initiated. After transplantation, the atherosclerosis may progress
even more. The rate of in vivo LDL oxidation is presumably
dependent on several factors. Renal insufficiency does not seem to
be a major determinant of the LDL oxidation as none of the
oxidation parameters were correlated with creatinine clearance in
patients or controls. The susceptibility of LDL for oxidation,
which is reflected in the lag phase of copper-induced in vitro LDL
oxidation, is probably an important factor determining the in vivo
LDL oxidation rate. The LDL size is one determinant of its
susceptibility for in vitro oxidation, small-dense LDL being more
susceptible than larger LDL [32, 33]. This was also found in the
patients and controls in the present study. Another factor influ-
encing the LDL oxidation in transplant patients may be the use of
cyclosporine A. Apanay and coworkers [11] found in renal
transplant patients with a high plasma cyclosporine level shorter
lag phases than in controls and in patients with lower cyclosporine
levels. Moreover, an inverse correlation between the amount of
LDL-associated cyclosporine and the lag phase was found to exist.
We found no correlation between the lag phase and the plasma
cyclosporine level, although the lag phases of the renal transplant
recipients tended to be shorter if compared to controls with the
same LDL subclass. Therefore, cyclosporine may have a small
effect on the lag phase, but it seems that the difference in the
mean LDL oxidation lag time between control and patient groups
is mainly due to the high number of subjects with small LDL in the
renal transplant group. Recently, we demonstrated that, in sub-
jects with coronary artery disease, autoantibodies against MDA-
LDL were higher in patients with the LDL subclass pattern B than
with the LDL subclass pattern A [41]. In the renal transplant
patients this was also the case. This suggests that not only in vitro,
but also in vivo, LDL of patients with the LDL subclass pattern B
is more readily oxidized than larger LDL. In this respect it is of
interest that Taylor and coworkers [50] showed that the oxidation
potential is higher in renal transplant recipients than in controls as
evidenced by higher plasma malondialdehyde levels, lower plasma
thiols and increased red cell superoxide dismutase. Thus several
factors may add to an enhanced LDL oxidation in the patients: a
larger number of patients with small-dense LDL, increased sus-
ceptibility for oxidation by cyclosporine and a higher overall
oxidation potential. The presence of small-dense LDL may be at
least in part metabolically explained. The LDL subclass pattern B
is associated with an increased (VLDL) triglyceride and low
HDL-C [38, 51]. In our study a lower LDL size was also associated
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with higher plasma triglyceride and lower HDL cholesterol levels.
If the lowering in LDL size is due to the increase in triglycerides,
the increased plasma triglyceride level may be one cause of
enhanced LDL oxidation. Supposing that increased LDL oxida-
tion contributes to the high atherosclerotic disease in the trans-
plant patients, a lowering of plasma triglycerides (if it leads to a
shift of LDL subclass pattern and subsequently less LDL oxida-
tion) may help to diminish the progression of atherosclerosis in
renal transplant patients.
In conclusion, our results show that in renal transplant recipi-
ents, there is increased incidence of the LDL subclass pattern B
with an increased susceptibility to oxidative modification. Proba-
bly LDL oxidation in vivo is also increased in transplant patients,
as indicated by increased values of autoantibodies against MDA-
LDL. These factors may play a role in the accelerated atherogen-
esis occurring after renal transplantation.
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